PRODUCT MONOGRAPH

PrPICATO®

ingenol mebutate

Topical Gel

0.015% and 0.05%

Chemotherapeutic for topical use (D06BX02)

LEO Pharma Inc.
Thornhill, Ontario
L3T 7W8
www.leo-pharma.com/canada

Control No.: 153285

© Registered trademark of LEO Pharma A/S used under license by LEO Pharma Inc., Thornhill, ON

Date of Preparation:
January 30, 2013
# Table of Contents

## PART I: HEALTH PROFESSIONAL INFORMATION
- SUMMARY PRODUCT INFORMATION .................................................. 3
- INDICATIONS AND CLINICAL USE .................................................. 3
- CONTRAINDICATIONS ................................................................. 3
- WARNINGS AND PRECAUTIONS .................................................... 4
- ADVERSE REACTIONS ................................................................. 6
- DOSAGE AND ADMINISTRATION .................................................... 10
- OVERDOSAGE ............................................................................ 11
- ACTION AND CLINICAL PHARMACOLOGY ...................................... 11
- STORAGE AND STABILITY ............................................................ 13
- DOSAGE FORMS, COMPOSITION AND PACKAGING ......................... 13

## PART II: SCIENTIFIC INFORMATION
- PHARMACEUTICAL INFORMATION ................................................... 14
- CLINICAL TRIALS ......................................................................... 15
- DETAILED PHARMACOLOGY ......................................................... 19
- TOXICOLOGY ................................................................................ 20
- REFERENCES ................................................................................ 22

## PART III: CONSUMER INFORMATION
........................................................................................................... 25
PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topical</td>
<td>Gel</td>
<td>For a complete listing see Dosage Forms, Composition and Packaging section.</td>
</tr>
<tr>
<td></td>
<td>0.015% strength contains 70 mcg ingenol mebutate per unit dose tube</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.05% strength contains 235 mcg ingenol mebutate per unit dose tube</td>
<td></td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

PICATO (ingenol mebutate) is indicated for:

- topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (AK) in adults.

Geriatrics (≥ 65 years): No overall differences in safety or efficacy were observed between patients aged 65 years and over compared with younger patients (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations).

Pediatrics (< 18 years): The safety and efficacy of PICATO in patients less than 18 years of age have not been established.

CONTRAINDICATIONS

- Hypersensitivity to the ingenol mebutate or to any of the excipients. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.
WARNINGS AND PRECAUTIONS

General
The efficacy of PICATO (ingenol mebutate) in the prevention of squamous cell carcinoma (SCC) associated with actinic keratosis (AK) has not been studied. The rate of SCC reported in the treatment area was comparable in patients treated with PICATO (0.3%) and in vehicle treated patients (0.3%) in the AK clinical studies. SCC in the treatment area was reported in no patients previously treated with PICATO in three prospective, observational long term 1 year follow-up studies.

Clinical data on re-treatment and treatment of more than one area with PICATO is not available (see DOSAGE AND ADMINISTRATION, Dosing Considerations).

Clinical data on treatment in immunocompromised patients is not available, but systemic risks are not expected since systemic exposure of ingenol mebutate was not detected following topical treatment with PICATO.

PICATO should not be used near the eyes, on the inside of the nostrils, on the inside of the ears, or on the lips.

Ophthalmologic
Severe eye disorders occurred more frequently in patients treated with PICATO than vehicle, including periorbital edema, eyelid edema, eye edema, eye pain, and eyelid ptosis in the AK clinical studies. These eye disorders may result from spreading of application site edema. All eye disorders resolved without sequelae.

Ingenol mebutate is a known ocular irritant. Precautions should be taken to avoid accidental exposure. If accidental exposure occurs, the eyes should be flushed immediately with large amounts of water, and the patient should seek medical care as soon as possible.

Gastrointestinal
PICATO (ingenol mebutate) must not be ingested. If accidental ingestion occurs the patient should drink plenty of water.
Skin
Severe local skin responses (LSRs) such as erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration can occur after topical application of PICATO. LSRs are common and the majority are mild to moderate. A treatment effect may not be adequately assessed until resolution of local skin responses.

Administration of PICATO is not recommended until the skin is healed from treatment with any previous medicinal product or surgical treatment.

Due to the irritant properties of ingenol mebutate, contact with skin outside the treatment area should be avoided. If there is inadvertent contact with skin not in the treatment area, the area must be washed with mild soap and water.

Carcinogenesis and Mutagenesis
Long-term animal carcinogenicity studies with ingenol mebutate have not been conducted. Ingenol mebutate was not genotoxic or clastogenic in a bacterial mutation (Ames) assay, mouse lymphoma cell assay, or rat in vivo micronucleus assay. Ingenol mebutate was positive in the Syrian hamster embryo (SHE) cell transformation test, which detects both genotoxic and epigenetic carcinogens.

Carcinogenic and mutagenic risks to humans receiving treatment with PICATO are considered unlikely since systemic exposure of ingenol mebutate was not detected following topical treatment.

Special Populations
Pregnant Women: There are no data from the use of PICATO in pregnant women. Embryo-fetal development studies in rabbits with intravenous ingenol mebutate demonstrated an increase in embryo-fetal mortality and an increased incidence of fetal visceral and skeletal variations (see TOXICOLOGY, Reproduction). Risks to humans receiving treatment with PICATO are considered unlikely since systemic exposure of ingenol mebutate was not detected following topical treatment. However, as a precautionary measure, it is preferable to avoid the use of
PICATO during pregnancy.

**Nursing Women:** No effects on breastfed newborns/infants are anticipated since systemic exposure of ingenol mebutate was not detected following topical treatment with PICATO. The nursing mother should be instructed that physical contact between her newborn/infant and the treated area should be avoided for a period of 6 hours after application of PICATO.

**Pediatrics (< 18 years):** The safety and efficacy of PICATO in patients less than 18 years of age have not been established.

**ADVERSE REACTIONS**

**Adverse Drug Reaction Overview**

The most frequently reported adverse drug reactions associated with PICATO (ingenol mebutate) treatment were general disorders and administration site disorders, including application site pain and application site pruritus.

Local Skin Responses (LSRs) were assessed independently in an effort to provide a better profile of the specific types of visible local skin reactions. LSRs included erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. LSRs are transient and typically occur within 1 day of treatment initiation and peak in intensity up to 1 week following completion of treatment. These effects typically resolve within 2 weeks for areas treated on the face and scalp and within 4 weeks for areas treated on the trunk and extremities.

**Clinical Trial Adverse Drug Reactions**

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

The adverse drug reaction profile described below reflects exposure to PICATO on a skin area of 25 cm² in 499 patients with actinic keratosis, including 274 patients exposed to PICATO at a
concentration of 0.015% once daily for 3 consecutive days on the face or scalp, and 225 subjects exposed to PICATO at a concentration of 0.05% once daily for two consecutive days on the trunk and extremities.

Adverse Drug Reactions that occurred in ≥1% of patients treated with PICATO are presented in Table 1 and Table 2. Adverse drug reactions were generally mild to moderate in severity.

<table>
<thead>
<tr>
<th>Table 1. Adverse Drug Reactions Occurring in ≥ 1 % of Patients Treated with PICATO Gel or Vehicle in Controlled Phase 3 Face/Scalp Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>MedDRA SOC (Preferred term)</td>
</tr>
<tr>
<td>General disorders and administration site disorders</td>
</tr>
<tr>
<td>Application site pain</td>
</tr>
<tr>
<td>Application site pruritus</td>
</tr>
<tr>
<td>Application site irritation</td>
</tr>
<tr>
<td>Infections and infestations</td>
</tr>
<tr>
<td>Application site infection</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
</tr>
<tr>
<td>Periorbital edema</td>
</tr>
<tr>
<td>Nervous system disorders</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>Eye Disorders</td>
</tr>
<tr>
<td>Eyelid edema</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Adverse Drug Reactions Occurring in ≥ 1 % of Patients Treated with PICATO Gel or Vehicle in Controlled Phase 3 Trunk/Extremities Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>MedDRA SOC (Preferred term)</td>
</tr>
<tr>
<td>General disorders and administration site disorders</td>
</tr>
<tr>
<td>Application site pruritus</td>
</tr>
<tr>
<td>Application site irritation</td>
</tr>
<tr>
<td>Application site pain</td>
</tr>
</tbody>
</table>

Less Common Clinical Trial Adverse Drug Reactions (<1%)  
Other less common adverse drug reactions (less than 1% but more than 0.5%) were for scalp/face: eye pain, application site discharge, and application site paraesthesia; for trunk/extremities: application site paraesthesia and application site warmth.
**Local Skin Responses**

LSRs were evaluated within the selected treatment area and graded by the investigator on a scale of 0 to 4 (see Table 3 and Table 4).

**Table 3. Investigator Assessment of Maximal Local Skin Reactions in the Treatment Area during the 57 Days Post Treatment Period (face/scalp studies)**

<table>
<thead>
<tr>
<th>Face and Scalp (n=545)</th>
<th>0.015% PICATO gel, once daily for 3 days</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Grade* &gt; Baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PICATO gel (n=274)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vehicle (n=271)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Skin reactions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema</td>
<td>258 (94%)</td>
<td>69 (25%)</td>
<td>25 (9%)</td>
<td>56 (20%)</td>
</tr>
<tr>
<td>Flaking / Scaling</td>
<td>233 (85%)</td>
<td>67 (25%)</td>
<td>52 (19%)</td>
<td>91 (33%)</td>
</tr>
<tr>
<td>Crusting</td>
<td>220 (80%)</td>
<td>46 (17%)</td>
<td>85 (31%)</td>
<td>64 (23%)</td>
</tr>
<tr>
<td>Swelling</td>
<td>217 (79%)</td>
<td>11 (4%)</td>
<td>88 (32%)</td>
<td>67 (24%)</td>
</tr>
<tr>
<td>Vesiculation / Pustulation</td>
<td>154 (56%)</td>
<td>1 (0%)</td>
<td>36 (13%)</td>
<td>53 (19%)</td>
</tr>
<tr>
<td>Erosion / Ulceration</td>
<td>87 (32%)</td>
<td>3 (1%)</td>
<td>55 (20%)</td>
<td>26 (9%)</td>
</tr>
</tbody>
</table>

*A grade of 0 represented no reaction present in the treated area, and a grade of 4 indicated a marked and discernable skin reaction that extended beyond the area treated.*
Table 4. Investigator Assessment of Maximal Local Skin Reactions in the Treatment Area during the 57 Days Post Treatment Period (trunk/extremities studies)

<table>
<thead>
<tr>
<th>Skin reactions</th>
<th>Any Grade* &gt; Baseline</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PICATO gel (n=225)</td>
<td>Vehicle (n=232)</td>
<td>PICATO gel (n=225)</td>
<td>PICATO gel (n=225)</td>
</tr>
<tr>
<td>Erythema</td>
<td>207 (92%)</td>
<td>43 (19%)</td>
<td>31 (14%)</td>
<td>94 (42%)</td>
</tr>
<tr>
<td>Flaking / Scaling</td>
<td>203 (90%)</td>
<td>44 (19%)</td>
<td>52 (23%)</td>
<td>86 (38%)</td>
</tr>
<tr>
<td>Crusting</td>
<td>167 (74%)</td>
<td>23 (10%)</td>
<td>105 (47%)</td>
<td>39 (17%)</td>
</tr>
<tr>
<td>Swelling</td>
<td>143 (64%)</td>
<td>13 (6%)</td>
<td>65 (29%)</td>
<td>51 (23%)</td>
</tr>
<tr>
<td>Vesiculation / Pustulation</td>
<td>98 (44%)</td>
<td>2 (1%)</td>
<td>46 (20%)</td>
<td>30 (13%)</td>
</tr>
<tr>
<td>Erosion / Ulceration</td>
<td>58 (26%)</td>
<td>6 (3%)</td>
<td>37 (16%)</td>
<td>15 (7%)</td>
</tr>
</tbody>
</table>

*A grade of 0 represented no reaction present in the treated area, and a grade of 4 indicated a marked and discernable skin reaction that extended beyond the area treated.

For patients treated on the face or scalp for 3 consecutive days, the majority of patients treated with PICATO gel, 0.015% had a maximum LSR score on Day 4, which returned to baseline or below by Day 15.

For patients treated on the trunk or extremities for 2 consecutive days, the majority of patients treated with PICATO gel 0.05% had a maximum LSR score on Days 3 or 8, which returned to baseline or below by Day 29.

**Long-term Safety Follow-up**
A total of 108 patients treated with PICATO on the face/scalp and 76 patients treated on the trunk/extremities were enrolled in three prospective, observational long-term follow-up studies. There were no adverse drug reactions reported in these studies (see CLINICAL TRIALS).

**DRUG INTERACTIONS**
No interaction studies have been performed. Interactions with systemically absorbed medicinal products are considered unlikely since systemic exposure of ingenol mebutate was not detected.
following topical treatment with PICATO (see ACTION AND CLINICAL PHARMACOLOGY).

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

For topical use only.

PICATO (ingenol mebutate) gel is not for oral, ophthalmic or intravaginal use.

Clinical data on treatment for more than one treatment course of 2 or 3 consecutive days is not available. Clinical data on treatment of more than one area is not available.

The treated area should not be covered with occlusive bandages after PICATO is applied.

**Recommended Dose and Dosage Adjustment**

**Actinic keratosis on the face and scalp:**

PICATO 0.015% gel should be applied to the treatment field area (25 cm²) once daily for 3 consecutive days.

**Actinic keratosis on the trunk and extremities:**

PICATO 0.05% gel should be applied to the treatment field area (25 cm²) once daily for 2 consecutive days.

**Geriatrics (≥ 65 years):** No dose adjustment is required (see ACTION & CLINICAL PHARMACOLOGY, Special Populations).

**Administration**

PICATO should be applied to the treatment field area as defined by the treating physician. Each tube contains enough gel to cover an area of approximately 25 cm² (e.g., 5 cm x 5 cm).

The gel from the unit dose tube should be squeezed onto the fingertip and spread evenly over the entire treatment area, allowing it to dry for 15 minutes. One unit dose tube should be used for the
field treatment area.

Patients should be instructed to wash their hands immediately after applying PICATO. If treating the hands, only the fingertip which is used for applying the gel should be washed. Washing and touching the treated area should be avoided for a period of 6 hours after the application of PICATO.

PICATO should not be applied immediately after taking a shower or less than 2 hours before bedtime

OVERDOSAGE
There has been no experience of overdose in clinical studies with PICATO (ingenol mebutate).

For management of a suspected drug overdose or accidental ingestion, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action
The mechanism of action of ingenol mebutate in actinic keratosis (AK) is not fully characterized since there is no adequate animal model of AK. *In vivo* and *in vitro* models using tumour cell lines, including squamous cell carcinoma, have shown a dual mechanism of action for the effects of ingenol mebutate: 1) direct cytotoxicity and 2) promoting an inflammatory response characterised by release of inflammatory cytokines and infiltration of immunocompetent cells.

Pharmacodynamics
At a high concentration (100 µg/ml) *in vitro* and *in vivo*, studies have shown that ingenol mebutate is cytotoxic.

At lower concentrations (10 to 100 ng/ml), ingenol mebutate activates both novel and classical protein kinase C (PKC) and is associated with immunostimulatory effects. Some classes of PKC
activators, such as phorbol esters, are known to be tumour promoters. Ingenol mebutate is structurally related to phorbol esters. The clinical significance of potential proliferative effects via activation of PKC by ingenol mebutate is unknown. However, no evidence of neoplasia was noted in 6 and 9-month dermal repeat dose studies in rats and minipigs (cyclic administration). The risk of tumour induction in humans receiving treatment with PICATO is considered very unlikely due to the short duration of treatment (2-3 days).

Exposure of isolated human keratinocytes to lower concentrations of ingenol mebutate (10 to 100 ng/ml) in vitro, was shown to induce release of the cytokines IL-8 and TNF-alpha and neutrophil activation. Both in vitro and in mice, ingenol mebutate induced IL-8 / murine IL-8 homologue MIP-2, TNF-alpha, and IL-1beta, all mediators of neutrophil recruitment and activation.

Topical treatment with ingenol mebutate gel in the squamous cell carcinoma model resulted in a localized and transient application site inflammatory reaction, which peaked after few days, and resolved within 2 weeks followed by scar resolution after 2 to 3 months. After 3 weeks of treatment with ingenol mebutate, treated mouse skin was similar to untreated skin in elasticity.

**Ultraviolet Light Exposure:** Studies have been conducted to assess the effects of UV irradiation on the skin following single and multiple applications of ingenol mebutate, 100 mcg/g. Ingenol mebutate gel did not demonstrate any potential for photo-irritation or photo-allergic effects.

**Pharmacokinetics**
The systemic pharmacokinetic profile of ingenol mebutate and its metabolites has not been characterised in humans due to an absence of quantifiable whole blood levels following topical administration.

*In vitro* studies to assess the potential of ingenol mebutate to inhibit or induce human cytochrome P450 (CYP) enzymes demonstrated that ingenol mebutate does not inhibit CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4, or induce CYP 1A2, 2C9, or 3A4.
Absorption: In humans, the highest concentration and treatment area evaluated was 0.05 µg/mm² of ingenol mebutate gel, 0.05% applied once daily to a 100 cm² area for two consecutive days. No systemic blood levels of ingenol mebutate or its two isomers PEP015 and PEP025 were quantifiable, i.e. concentrations were below the LLOQ (0.1 ng/mL).

**Special Populations and Conditions**

**Pediatrics (< 18 years):** The safety and efficacy of PICATO (ingenol mebutate) in patients less than 18 years of age have not been established.

**Geriatrics (≥ 65 years):** Of the 1,165 patients treated with PICATO in the actinic keratosis clinical studies, 656 patients (56%) were 65 years and older (9), while 241 patients (21%) were 75 years and older. No overall differences in safety or efficacy were observed between younger and older patients.

**STORAGE AND STABILITY**

PICATO (ingenol mebutate) gel should be stored in a refrigerator (2°C to 8°C).

Keep out of reach of children.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

PICATO (ingenol mebutate) is a clear colourless gel.

**PICATO, 0.015% Gel**

Each unit dose tube contains 70 mcg of ingenol mebutate in 0.47 g gel.

Available as: 3 unit dose tubes per carton.

**PICATO, 0.05% Gel**

Each unit dose tube contains 235 mcg of ingenol mebutate in 0.47 g gel.

Available as: 2 unit dose tubes per carton.

Non-medicinal ingredients: Isopropyl alcohol, hydroxyethyl cellulose, benzyl alcohol, citric acid monohydrate, sodium citrate, purified water.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name (I.N.N.): ingenol mebutate
Chemical name: 2-Butenoic acid, 2-methyl-, (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-1a,2,5,5a,6,9,10,10a-octahydro-5,5a-dihydroxy-4-(hydroxymethyl)-1,7,9-tetramethyl-11-oxo-1H-2,8a-methanocyclopenta[a]cyclopropa[e]cyclodecen-6-yl ester, (2Z) -
Alternative chemical name: (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1H 2,8a-methanocyclopenta[a]cyclopropa[e]cyclodecen-6-yl (2Z) 2 methylbut-2-enoate.
Laboratory code name: PEP005
Molecular formula: C_{25}H_{34}O_{6}
Molecular mass: 430.53 g/mol
Chirality: Eight chiral centres with specific optical rotation range 44° - 49°

Structural formula:

![Structural formula image]

Physicochemical properties:

Physical form: White to pale yellow crystalline powder
Solubility: Freely soluble in benzyl alcohol and isopropyl alcohol, soluble in methanol, ethanol, acetonitrile and acetone, very slightly soluble in ethanol-water (1:3) and practically insoluble in n-heptane and water
Melting point: 154.1 °C – 156.8 °C
pH: Weakly acidic, pKa 12.7
CLINICAL TRIALS
The efficacy and safety of PICATO (ingenol mebutate) 0.015% gel administered on the face or scalp for 3 consecutive days, and 0.05% gel administered on the trunk or extremities for 2 consecutive days was studied in four multi-centre, double-blind, randomized, parallel group, vehicle-controlled studies. For both treatment locations, eligible patients had 4 to 8 clinically typical, visible, discrete, non-hyperkeratotic, non-hypertrophic, actinic keratosis (AK) lesions within a contiguous 25 cm² treatment area. On each scheduled dosing day, the study gel was applied to the entire treatment area (25 cm²). Patients continued in the studies for an 8 week follow-up period during which they returned for clinical observations and safety monitoring.

The efficacy of PICATO in AK is based on clinical clearance; histological assessment of clearance was not performed. The primary efficacy endpoint was complete clearance rate, defined as the proportion of patients at Day 57 with no clinically visible AK lesions in the selected treatment area. The secondary endpoint was partial clearance rate, defined as the proportion of patients at Day 57 with a 75% or greater reduction in the number of clinically visible AK lesions identified at baseline in the selected treatment area. The median percent reduction from baseline in the total number of AK lesions at Day 57 was also determined.

Face and Scalp
Study patients (n=547) ranged from 34 to 89 years of age (mean 64 years) and 94% had Fitzpatrick skin type I, II, or III. Approximately 85% of subjects were male, and all subjects were Caucasian. A total of 536 subjects (98%) completed these studies (see Table 5).
### Table 5. Clinical Efficacy Studies of Actinic Keratosis on the Face and Scalp

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study patients by dose group</th>
<th>Mean age (Range) years</th>
<th>Gender by dose group M/F</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEP005-016</td>
<td>Multi-centre, double-blind, randomized, parallel group, vehicle-controlled</td>
<td>PICATO 0.015% or vehicle, once a day topical, for 3 consecutive days</td>
<td>135 134</td>
<td>63.5 (37–88) 63.0 (40–85)</td>
<td>116/19 120/14</td>
</tr>
<tr>
<td>PEP005-025</td>
<td>Multi-centre, double-blind, randomized parallel group, vehicle-controlled</td>
<td>PICATO 0.015% or vehicle, once a day topical, for 3 consecutive days</td>
<td>142 136</td>
<td>64.8 (34–88) 65.0 (46–89)</td>
<td>117/25 112/24</td>
</tr>
</tbody>
</table>

At Day 57, patients treated with PICATO gel had statistically significantly higher complete and partial clearance rates than patients treated with vehicle gel ($p < 0.001$). The median percent reduction in actinic keratosis lesions was higher in the group treated with ingenol mebutate compared to the vehicle group (see Table 6). Efficacy varied between anatomical locations (Table 7). Within each group, the complete and partial clearance rates were higher in patients treated with PICATO gel than patients treated with vehicle.

### Table 6. Rates of Patients with Complete and Partial Clearance and Percent (%) Reduction on the Face and Scalp

<table>
<thead>
<tr>
<th>Study PEP005-016</th>
<th>Study PEP005-025</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PICATO 0.015% gel (n=135)</td>
</tr>
<tr>
<td>Complete Clearance Rate&lt;sup&gt;a&lt;/sup&gt;</td>
<td>50 (37%)&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Partial Clearance Rate (≥ 75%)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>81 (60%)&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Median % Reduction&lt;sup&gt;c&lt;/sup&gt;</td>
<td>83%</td>
</tr>
</tbody>
</table>

<sup>a</sup> Complete clearance rate was defined as the proportion of patients with no (zero) clinically visible actinic keratosis lesions in the treatment area.

<sup>b</sup> Partial clearance rate was defined as the percentage of patients in whom 75% or more of the number of baseline actinic keratosis lesions were cleared.

<sup>c</sup> Median percent (%) reduction in actinic keratosis lesions compared to baseline.

<sup>d</sup> $p<0.001$; compared to vehicle by Cochran-Mantel-Haenszel test stratified by study site.
Table 7. Number and Rate of Patients with Complete and Partial Clearance at Day 57 by Anatomical Location (Face and Scalp Studies PEP005-016 and PEP005-025 Combined)

<table>
<thead>
<tr>
<th></th>
<th>Complete Clearance</th>
<th>Partial Clearance (≥ 75%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PICATO 0.015 % gel (n=277)</td>
<td>Vehicle (n=270)</td>
</tr>
<tr>
<td>Face</td>
<td>104/220 47%</td>
<td>9/220 4%</td>
</tr>
<tr>
<td>Scalp</td>
<td>13/57 23%</td>
<td>1/50 2%</td>
</tr>
</tbody>
</table>

The safety of PICATO 0.015% gel treatment was assessed up to day 57 and ingenol mebutate gel was found to be well tolerated. All adverse drug reactions and local skin responses resolved without sequelae.

**Trunk and Extremities**

Study patients (n=458) ranged from 34 to 89 years of age (mean 66 years) and 94% had Fitzpatrick skin type I, II, or III. Approximately 62% of subjects were male, and all subjects were Caucasian. A total of 447 subjects (98%) completed these studies (see Table 8).

Table 8. Clinical Efficacy Studies of Actinic Keratosis on the Trunk and Extremities

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study patients by dose group</th>
<th>Mean age (Range) years</th>
<th>Gender by dose group M/F</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEP005-014</td>
<td>Multi-centre, double-blind, randomized, parallel group, vehicle-controlled</td>
<td>PICATO 0.05% or vehicle, once a day topical, for 2 consecutive days</td>
<td>126 129</td>
<td>67.2 (43–88) 66.9 (36–87)</td>
<td>86/40 73/56</td>
</tr>
<tr>
<td>PEP005-028</td>
<td>Multi-centre, double-blind, randomized, parallel group, vehicle-controlled</td>
<td>PICATO 0.05% or vehicle, once a day topical, for 2 consecutive days</td>
<td>100 103</td>
<td>65.3 (43–87) 64.9 (34–89)</td>
<td>59/41 68/35</td>
</tr>
</tbody>
</table>

At Day 57, patients treated with PICATO gel had statistically significantly higher complete and partial clearance rates than patients treated with vehicle gel (p < 0.001). The median percent reduction in actinic keratosis lesions was higher in the group treated with ingenol mebutate compared to the vehicle group (see Table 9). Efficacy varied between anatomical locations.
Within each group, the complete and partial clearance rates were higher in patients treated with PICATO gel than patients treated with vehicle.

Table 9. Rates of Patients with Complete and Partial Clearance and Percent (%) Reduction on the Trunk and Extremities

<table>
<thead>
<tr>
<th></th>
<th>Study PEP005-014</th>
<th>Study PEP005-028</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PICATO 0.05% gel</td>
<td>Vehicle</td>
</tr>
<tr>
<td></td>
<td>(n=126)</td>
<td>(n=129)</td>
</tr>
<tr>
<td>Complete Clearance Rate&lt;sup&gt;a&lt;/sup&gt;</td>
<td>35 (28%)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>6 (5%)</td>
</tr>
<tr>
<td>Partial Clearance Rate (≥ 75%)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>56 (44%)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>9 (7%)</td>
</tr>
<tr>
<td>Median % Reduction&lt;sup&gt;c&lt;/sup&gt;</td>
<td>69 %</td>
<td>0 %</td>
</tr>
</tbody>
</table>

<sup>a</sup> Complete clearance rate was defined as the proportion of patients with no (zero) clinically visible actinic keratosis lesions in the treatment area.

<sup>b</sup> Partial clearance rate was defined as the percentage of patients in whom 75% or more of the number of baseline actinic keratosis lesions were cleared.

<sup>c</sup> Median percent (%) reduction in actinic keratosis lesions compared to baseline.

<sup>d</sup> p<0.001; compared to vehicle by Cochran-Mantel-Haenszel test stratified by study site.

Table 10. Number and Rate of Patients with Complete and Partial Clearance at Day 57 by Anatomical Location (Trunk and Extremities Studies PEP005-014 and PEP005-028 Combined)

<table>
<thead>
<tr>
<th></th>
<th>Complete Clearance</th>
<th>Partial Clearance (≥ 75%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PICATO 0.05 % gel</td>
<td>Vehicle</td>
</tr>
<tr>
<td></td>
<td>(n=226)</td>
<td>(n=232)</td>
</tr>
<tr>
<td>Arm</td>
<td>49/142 35%</td>
<td>7/149 5%</td>
</tr>
<tr>
<td>Back of Hand</td>
<td>10/54 19%</td>
<td>0/56 0%</td>
</tr>
<tr>
<td>Chest</td>
<td>11/14 79%</td>
<td>2/11 18%</td>
</tr>
<tr>
<td>Other&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7/16 44%</td>
<td>2/16 13%</td>
</tr>
</tbody>
</table>

<sup>a</sup> Other includes shoulder, back, leg.

The safety of PICATO 0.05% gel treatment for 2 days was assessed up to day 57 and ingenol mebutate gel was found to be well-tolerated. All adverse drug reactions and local skin responses resolved without sequelae.
**Long-term Efficacy**

Three prospective, observational long-term 1 year follow-up studies were conducted to evaluate sustained efficacy by recurrence of actinic keratosis lesions in the treatment field, and safety in patients who had received treatment with PICATO. One study included patients treated with PICATO 0.015% on the face or scalp for 3 days and two studies included patients treated with PICATO 0.05% on the trunk or extremities for 2 days. Only those patients who achieved complete clearance in the treated area at the end of the phase 3 studies (Day 57) were eligible for long term follow-up. Patients were followed every 3 months for 12 months (see Tables 11).

<table>
<thead>
<tr>
<th>Table 11. Rate of Recurrence of Actinic Keratosis Lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td><strong>PICATO 0.015% gel</strong></td>
</tr>
<tr>
<td><strong>Face and Scalp</strong> (n=108)</td>
</tr>
<tr>
<td>Recurrence Rate 12 months KM estimate (95% CI)a</td>
</tr>
<tr>
<td>Lesion Based Recurrence Rateb 12 months Mean (SD)</td>
</tr>
<tr>
<td><strong>PICATO 0.05% gel</strong></td>
</tr>
<tr>
<td><strong>Trunk and Extremities</strong> (n=76c)</td>
</tr>
<tr>
<td>Lesion Based Recurrence Rateb 12 months Mean (SD)</td>
</tr>
</tbody>
</table>

a The recurrence rate is the Kaplan-Meier (KM) estimate at the target study date of the visit expressed as a percentage (95% CI). Recurrence was defined as any identified actinic keratosis lesion in the previously treated area for patients who achieved complete clearance at day 57 in the previous phase 3 studies.

b The lesion-based recurrence rate for each patient defined as the ratio of the number of actinic keratosis lesions at 12 months to the number of lesions at baseline in the previous phase 3 studies.

c Of these, 38 subjects were previously treated in a vehicle controlled phase 3 study and 38 subjects were previously treated in an uncontrolled phase 3 study.

**Local Tolerability**

Results of 3 topical safety studies in healthy volunteers showed that PICATO gel did not produce a sensitization response and results indicated no potential for dermal phototoxicity, or dermal photosensitization.

**DETAILED PHARMACOLOGY**

There is no adequate disease model for AK. Therefore, in vivo and in vitro models using tumour cell lines, including squamous cell carcinoma, were used to investigate the mechanism of action of ingenol mebutate (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics).

In safety pharmacology studies, ingenol mebutate did not inhibit I_{Kr} ion channel activity in vitro.
or adversely affect QT intervals or electrocardiogram waveform morphology *in vivo* in dogs at the highest doses evaluated (5 µg/mL and 15 µg/kg, respectively). Mild haemodynamic effects (≥5 µg/kg) and increased respiration and minute volume ventilation (≥7.5 µg/kg) were observed in dogs following a single IV administration. No significant effects on central nervous system parameters were noted in rats following IV administration of ≤10 µg/kg ingenol mebutate.

**TOXICOLOGY**

In all topical administration studies, dose limiting toxicity was associated with the severity of the irritant response to ingenol mebutate gel administration. Dose- and frequency-dependent skin responses in rats and minipigs, characterised by erythema and oedema, and microscopic observations of acanthosis, dermal inflammation/fibrosis, epidermal hyperplasia, erosion/ulceration, and scab formation, were similar between species and were consistent across studies.

Gross and histological observations of dermal irritation were reversible at all tested dose levels in both rats and minipigs.

In topical administration studies, single or three daily repeat doses of 0.1% ingenol mebutate up to 500 µg on 150-600 mm² in rats or minipigs did not produce mortality or systemic toxicity.

Chronic topical application of 0.02% ingenol mebutate gel up to 30 µg on 600 mm² for 3 consecutive days repeated monthly for 6 months in rats and 0.03% ingenol mebutate gel up to 180 µg on 2400 mm² for 3 consecutive days repeated monthly for 41 weeks in minipigs also demonstrated no systemic toxicity.

Clinical pathology findings were limited to occasional increases in circulating neutrophils and/or monocytes in rats which were associated with acute/chronic dermal inflammation.

**Reproduction**

In rats, ingenol mebutate was not associated with fetal developmental effects at IV doses up to 5 µg/kg/day (30 µg/m²/day). In rabbits, dams receiving 4 µg/kg/day showed an increased incidence of early embryonic deaths compared with the controls (13% vs 7%). Minor foetal
Abnormalities were also observed at an increased incidence in the foetuses of ingenol mebutate treated dams (at doses of 1-4µg/kg/day), including variation in the origin of arteries arising directly from the aortic arch, unilateral/bilateral rib costal cartilage not attached to sternum, incompletely ossified cervical vertebral arches and jugal connected/fused to the zygomatic process of the maxilla.

No fertility studies have been performed with ingenol mebutate.

**Carcinogenesis and Mutagenesis**

Carcinogenicity studies with ingenol mebutate have not been conducted.

Ingenol mebutate was not mutagenic in an *in vitro* Ames test, mouse lymphoma assay, and *in vivo* rat micronucleus test. An *in vitro* Syrian hamster embryonic (SHE) cell transformation assay was positive. The SHE transformation assay gave a positive result after the 24 h and 7 day exposure periods. There was an increase in toxicity (decrease in relative plating efficiency) and increase in morphologically transformed colonies (MTC). Toxicity noted at ≥ 0.05 µg/mL at 24 h and after 7 days. A statistical increase in MTC was seen from 0.1 µg/mL at 24 h and 0.025 µg/mL at 7 days.

A 6-month repeat dose IV rat study in 154 rats found that one male and one female dosed twice weekly with 15 µg/kg had a kidney tubular adenoma and tubular hyperplasia of the kidney. A pituitary adenoma was also present in the female with the renal adenoma. At the 1-month recovery kill, one male had a thyroid follicular cell carcinoma. There was no evidence of neoplasia at lower IV doses or in the 6 month dermal rat and 41 week dermal minipig repeat dose studies.
REFERENCES


24. A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) Gel, 0.05% in patients with actinic keratoses on non-head locations (REGION-Ia; PEP005-014) 2010 Sep 16 (data on file)

25. A multi-center, Randomized, parallel group, double-blind, vehicle-controlled study to evaluate the Efficacy and safety of PEP005 (ingenol mebutate) Gel, 0.05% In patients with actinic keratoses ON non-head locations (REGION-Ib; PEP005-028) 2010 Sep 8 (data on file)
26. A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) Gel, 0.015% in patients with actinic keratoses on the head (face or scalp). (REGION-IIa; PEP005-016) 2010 Sep 8 (data on file)

27. A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) Gel, 0.015% in patients with actinic keratoses on the head (face or scalp). (REGION-IIb; PEP005-025) 2010 Sep 8 (data on file)
PART III: CONSUMER INFORMATION

Picato® (ingenol mebutate)

Ingenol mebutate gel

This leaflet is part III of a three-part "Product Monograph" published when Picato® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Picato®. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
Picato® is used for the topical treatment of Actinic Keratosis.

Actinic Keratosis (AK) lesions are thick, hard, scaly patches on skin that has been damaged by too much sun (UV) exposure ( ).

What it does:
Picato® gel contains ingenol mebutate which is thought to be toxic to cells and promote a local inflammatory response.

When it should not be used:
Do not use Picato® gel if you are allergic (hypersensitive) to ingenol mebutate or any of the ingredients in the gel.

What the medicinal ingredient is:
Picato® gel contains ingenol mebutate.

What the important nonmedicinal ingredients are:
Picato® gel contains isopropyl alcohol, hydroxyethyl cellulose, citric acid monohydrate, sodium citrate, benzyl alcohol and purified water.

What dosage forms it comes in:
Picato® is a clear, colourless gel available in 2 strengths.
Picato® gel 0.015 %: Each carton contains 3 unit dose tubes
Picato® gel 0.05 %: Each carton contains 2 unit dose tubes

WARNINGS AND PRECAUTIONS

- Do not apply the gel near the eyes. Picato® gel is irritating to the eyes. If accidental application to the eye occurs, flush the area with plenty of water and seek medical care immediately
- Do not apply the gel on the inside of the nostrils, on the inside of the ears, on the lips, or on skin outside the treatment area as defined by your doctor.
- Make sure that the skin has healed from the other treatments or surgery before applying Picato® gel.
- If Picato® gel is accidentally swallowed drink plenty of water and seek medical care immediately.
- Picato® gel has not been studied in patients under 18 years of age.

BEFORE you use Picato® gel talk to your doctor or pharmacist if you:
- Are pregnant or planning to become pregnant.
- Are breastfeeding.
- Have had other treatments for AK.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including non-prescription medicines (such as vitamins, herbal remedies, etc.). It is not known if Picato® gel and other medicines can affect each other.

PROPER USE OF THIS MEDICATION

Always use Picato® gel exactly as prescribed by your doctor and only on the area(s) of skin to be treated.

Usual dose:
- For treatment of AK on the face and scalp, use one unit dose tube of 0.015% gel once daily for 3 days in a row.
- For treatment of AK on the body, arms, hands and legs, use one unit dose tube of 0.05% gel once daily for 2 days in a row.

Instructions for use:
- Open a new tube each time you use Picato® gel. Remove the cap from the tube just before using.
- Squeeze the contents from one tube onto your fingertip.
- One tube has enough gel to cover about a 25 cm² (5 cm x 5 cm) area of skin.
- Gently rub the gel over the affected skin area.
- Allow the area to dry for 15 minutes. Avoid touching the treated skin area.
- Wash your hands immediately after applying the gel. If you are treating your hands, you should only wash the fingertip you used for applying the gel.
- Do not touch the treated area yourself or allow anyone or any pets to touch the treated skin area for a period of 6 hours after applying Picato® gel.
- Do not wash the skin areas where you applied Picato® gel for at least 6 hours after you apply it.
- Do not apply Picato® gel immediately after taking a shower or less than 2 hours before bedtime.
- Do not cover the treated skin area with a bandage or other type of dressing after you have applied Picato® gel.
IMPORTANT: PLEASE READ

LEO®

PICATO® (ingenol mebutate) Product Monograph, version 1.0

Page 26 of 26

HOW TO STORE IT

Store Picato® gel in a refrigerator (2°C to 8°C).

Keep Picato® gel out of the reach of children and pets.

Do not use Picato® gel after the expiry date (EXP). Tubes should not be re-used once opened.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
  Health Canada
  Postal Locator 0701D
  Ottawa, Ontario
  K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at: www.leo-pharma.com/canada or by contacting the sponsor, LEO Pharma Inc., at: 1-800-668-7234.

This leaflet was prepared by LEO Pharma Inc.

© Registered trademark of LEO Pharma A/S used under license by LEO Pharma Inc., Thornhill, L3T 7W8

Last revised: January 30, 2013

Overdose:

In case of drug overdose or accidental ingestion, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose, contact your doctor.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Side effects with Picato® include:

The most common side effects: local skin reactions at the treatment site. These include redness, flaking, scabbing and crustung, swelling, blister or ulcer, skin that becomes hard or thickened, and peeling skin. These reactions can start within one day of treatment and may get worse for up to one week after you have stopped using Picato®. These will usually get better within 2 weeks from when you started treatment on the face and scalp, and within 4 weeks from when you started treatment on body, arms, hands and legs. If these reactions do not improve, see your doctor.

Common side effects: pain, itching, skin irritation or infection at the treatment area, swelling around the eyes, and headache.

Talk to your Health Care Provider if you have questions about your treatment or side effects.